CA-IB cuts Hungary Egis, Richter target prices over local, Russian changes

Pharma

CA-IB has reduced its target price on Hungarian pharmaceutical companies Egis and Richter to Ft 31,473 from Ft 36,540 and to Ft 45,298, respectively, following a revision of its model over unfavorable changes to come in Hungary's drug subsidy regime and Russia DLO program.

While analyst Katalin Dani cut the TP on Egis Nyrt (in an analysis issued last week) by nearly 14%, she maintained her “Buy” recommendation on the stock. Dani's rating on Richter Gedeon Nyrt is “Hold”. The analyst underlined that if next year's drugs budget were to be set Ft 320 billion (gross Ft 440 billion) - which currently looks highly likely - and drug spending increased by 10% year-on-year, Richter would need to repay additional Ft 3 billion and Egis another Ft 2.5 billion into the drugs budget. This case, Dani would further trim her target prices to Ft 28,355 on Egis and to Ft 43,493 on Richter. (portfolio.hu)

SUPPORT THE BUDAPEST BUSINESS JOURNAL

Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.

Support the BBJ

Industry